Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Opat

Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities

Hematological Oncology

English

Interim Update From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory Follicular Lymphoma

Hematological Oncology

English

Short Diagnosis-To-Treatment Interval Is Associated With High Risk and Poor Outcomes in Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

R-Ivac Salvage Therapy in Relapsed and Refractory DLBCL

Hematological Oncology

English

Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Hematological Oncology

English

Bruton's Tyrosine Kinase (Btk) Inhibitor BGB-3111 Demonstrates High Very Good Partial Response (Vgpr) Rate in Patients With Waldenström Macroglobulinemia (Wm)

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Opat

Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities

Interim Update From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory Follicular Lymphoma

Short Diagnosis-To-Treatment Interval Is Associated With High Risk and Poor Outcomes in Diffuse Large B-Cell Lymphoma

R-Ivac Salvage Therapy in Relapsed and Refractory DLBCL

Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Bruton's Tyrosine Kinase (Btk) Inhibitor BGB-3111 Demonstrates High Very Good Partial Response (Vgpr) Rate in Patients With Waldenström Macroglobulinemia (Wm)